Diagonal Bio publishes interim report for the third quarter of 2025
Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") hereby publishes its interim report for the third quarter of 2025. Below is a brief summary. The full report is available on Diagonal Bio's website (www.diagonalbio.com) and as an attached file.
Summary of the interim report for the third quarter of 2025
2025-07-01 — 2025-09-30 ( July-September 2025 )
- Net sales amounted to 45 KSEK (0 KSEK), capitalised development contributed with 238 KSEK
(248 KSEK), and other operating income amounted to 0 KSEK (0 KSEK).
- The net loss amounted to -2 042 KSEK (-1 242 KSEK).
- Operating profit per net weighted average share amounted to -0.001 SEK (0 SEK).
- Cash flow during the third quarter amounted to -1 002 KSEK (-2 428 KSEK).
- Cash and cash equivalents at the end of the period amounted to 1 737 KSEK (1 730 KSEK).
Significant events during the third quarter of 2025
- July 7, Diagonal Bio announced that the Company had filed a patent
application with the Swedish Intellectual Property Office (PRV), covering
a novel computational method that significantly improves the design
of LAMP primers – a critical component in molecular analysis. - August 20, Diagonal Bio announced that the Company had received
a confirmation from the Japanese Patent Office that the patent
application regarding “A method of measuring the ph of a sample”
(no.: JP7655939) had been granted in Japan. - September 18, Diagonal Bio announced that Stall Courant, one of
Sweden’s leading international horse trotting and breeding stables,
had placed an order for LAMPLify. The stable is managed by the
internationally renowned trotting trainer Sabine Kagebrant and home
to more than 125 horses. Stall Courant chose a 36-month leasing
agreement through Svea Bank, which shows both confidence in the
technology and a long-term commitment. - September 23, Diagonal Bio announced the expansion of its equine
testing panel to include the detection of Equine Herpesvirus type 2
(EHV-2). This broadens the Company’s product portfolio and addresses
an unmet need in equine health.
Significant events since 30 September 2025
- October 3, Diagonal Bio announced that the Company had initiated
a collaboration with Swedish Veterinary Agency (SVA) to support
the evaluation of testing for equine coronavirus in nasal swabs. The
project runs during October and is carried out under the supervision
of Johanna Lindahl, State veterinarian and Professor in global infection
biology. - October 13, Diagonal Bio announced the launch of its new website,
marking an important step in the implementation of the Company’s
strategy to strengthen its commercial presence and focus on the
animal health market, particularly within the equine segment.
For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO
Phone: +46 70 305 24 88
E-mail: kw@diagonalbio.com
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.